Statmed Sp. z o.o
Statmed Sp. z o.o is recorded as a service provider in 35 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 35 trials · Latest update first
An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who have completed the pediatric ORION-16 , ORION-13, ORION-20, or ORION-19 studies (VICTORION-PEDS-OLE)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS-2)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind 2-arm NEPTUNUS extension study followed by an open-label single-arm study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’s syndrome
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheumatica (PMR)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The trial enrolled 381 participants across 134 investigative sites in 27 countries.
- EEA countries enrolled 199 of 381 participants; the largest EEA enrollment was in France (45), the Czech Republic (33), and Germany (27).
These findings describe the trial, not the service provider’s performance or responsibility.
A multicenter, double-blind, placebo-controlled, randomized withdrawal and open-label extension study followed by long-term open-label treatment cycles to assess the efficacy, safety and tolerability of remibrutinib (LOU064) in adult chronic spontaneous urticaria patients who completed the preceding remibrutinib Phase 3 studies.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A global, multicenter, randomized, double-blind, double-dummy, parallel-group, Phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib 25 mg b.i.d. in comparison to placebo with omalizumab 300 mg every 4 weeks as active control over 52 weeks in adult patients with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines and an open-label 52-week optional extension to assess long-term efficacy, safety and tolerability of remibrutinib 25 mg b.i.d.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, two-period crossover study to demonstrate the comparability of pharmacokinetics of subcutaneous ianalumab between 2mL auto-injector/2mL pre-filled syringe with 1 mL pre-filled syringe in adult participants with autoimmune disease
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenitis suppurativa
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, placebo controlled, investigator and participant-blinded study, investigating safety, tolerability and efficacy of RHH646 in participants with knee osteoarthritis
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Statmed Sp. z o.o?
The 2026-10-09 snapshot links Statmed Sp. z o.o to 35 distinct CTIS trials. Recorded services include Compensation for patients travel to the clinical site, Medicinal product management. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Statmed Sp. z o.o?
The most frequently recorded therapeutic areas are Immunology, Rheumatology, Cardiology, Dermatology. Recorded phases include Phase 3, Phase 1, Phase 2, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Statmed Sp. z o.o conducted?
The linked trials record locations in 26 countries, including Poland, Spain, Germany, Italy, Czechia. These are trial locations, not confirmed office locations or countries where Statmed Sp. z o.o delivered services.
What can this page tell me about Statmed Sp. z o.o's trial experience?
Browse 35 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Statmed Sp. z o.o. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- STATMED Sp. z o. o.
- Statmed Sp. z o.o.